Characterization of an antibody that can detect the Kai1/CD82 murine metastasis suppressor

Prostate

Volumn 66, Issue 6, 2006, Pages 567-577

  Custer, Mary C ^a   Risinger, John I ^a   Hoover, Shelley ^a   Simpson, R Mark ^a   Patterson, Tricia ^a   Barrett, J Carl ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

CD82; KAI1; Tetraspanins

Indexed keywords

C33; CD82 ANTIGEN; CD82 MONOCLONAL ANTIBODY; CD82 POLYCLONAL ANTIBODY; METASTASIS SUPPRESSOR PROTEIN; MK35; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; PROTEIN; TETRASPANIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ANTIGEN DETECTION; ANTIGEN RECOGNITION; ARTICLE; CROSS REACTION; FEMALE; FLOW CYTOMETRY; IMMUNIZATION; IMMUNOBLOTTING; IMMUNODETECTION; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; PROTEIN FAMILY; RABBIT; TISSUE DISTRIBUTION;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES; CELL LINE, TUMOR; DNA PRIMERS; FLOW CYTOMETRY; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; KANGAI-1 PROTEIN; MALE; MICE; MOLECULAR SEQUENCE DATA; NEOPLASM METASTASIS; PEPTIDE FRAGMENTS; POLYMERASE CHAIN REACTION; PROSTATIC NEOPLASMS; TRANSFECTION;

EID: 33645936307     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20386     Document Type: Article

References (21)

1. Imai T, Fukudome K, Takagi S, Nagira M, Furuse M, Fukuhara N, Nishimura M, Hinuma Y, Yoshie O. C33 antigen recognized by monoclonal antibodies inhibitory to human T cell leukemia virus type 1-induced syncytium formation is a member of a new family of transmembrane proteins including CD9, CD37, CD53, and CD63. J Immunol 1992;149(9):2879-2886.
2. Horejsi V, Vlcek C. Novel structurally distinct family of leucocyte surface glycoproteins including CD9, CD37, CD53 and CD63. FEBS Lett 1991;288(1-2):1-4.
3. Bienstock RJ, Barrett JC. KAI1, a prostate metastasis suppressor: Prediction of solvated structure and interactions with binding partners; integrins, cadherins, and cell-surface receptor proteins. Mol Carcinog 2001;32(3):139-153.
4. Lebel-Binay S, Gil ML, Lagaudriere C, Miloux B, Marchiol-Fournigault C, Quillet-Mary A, Lopez M, Fradelizi D, Conjeaud H. Further characterization of CD82/IA4 antigen (type III surface protein): An activation/differentiation marker of mononuclear cells. Cell Immunol 1994;154(1):468-483.
5. Lagaudriere-Gesbert C, Lebel-Binay S, Hubeau C, Fradelizi D, Conjeaud H. Signaling through the tetraspanin CD82 triggers its association with the cytoskeleton leading to sustained morphological changes and T cell activation. Eur J Immunol 1998;28(12):4332-4344.
6. Maecker HT, Todd SC, Levy S. The tetraspanin superfamily: Molecular facilitators. FASEB J 1997;11(6):428-442.
7. Tonoli H, Barrett JC. CD82 metastasis suppressor gene: a potential target for new therapeutics? Trends Mol Med 2005 (in press).
8. Dong JT, Lamb PW, Rinker-Schaeffer CW, Vukanovic J, Ichikawa T, Isaacs JT, Barrett JC. KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science 1995;268(5212):884-886.
9. Takaoka A, Hinoda Y, Sato S, Itoh F, Adachi M, Hareyama M, Imai K. Reduced invasive and metastatic potentials of KAI1-transfected melanoma cells. Jpn J Cancer Res 1998;89(4):397-404.
10. White A, Lamb PW, Barrett JC. Frequent downregulation of the KAI1 (CD82) metastasis suppressor protein in human cancer cell lines. Oncogene 1998;16(24):3143-3149.
11. Ueda T, Ichikawa T, Tamaru J, Mikata A, Akakura K, Akimoto S, Imai T, Yoshie O, Shiraishi T, Yatani R, Ito H, Shimazaki J. Expression of the KAI1 protein in benign prostatic hyperplasia and prostate cancer. Am J Pathol 1996;149(5):1435-1440.
12. Adachi M, Taki T, Ieki Y, Huang CL, Higashiyama M, Miyake M. Correlation of KAI1/CD82 gene expression with good prognosis in patients with non-small cell lung cancer. Cancer Res 1996;56(8):1751-1755.
13. Adachi M, Taki T, Ieki Y, Ko S, Higashiyama S, Kodama K, Doi S, Miyake M. [KAI1/CD82 and ME491/CD63 expression in non-small-cell carcinoma of the lung and prognosis]. Nippon Kyobu Geka Gakkai Zasshi 1997;45(3):398-401.
14. Lombardi DP, Geradts J, Foley JF, Chiao C, Lamb PW, Barrett JC. Loss of KAI1 expression in the progression of colorectal cancer. Cancer Res 1999;59(22):5724-5731.
15. Farhadieh RD, Smee R, Ow K, Yang JL, Russell PJ, Crouch R, Jackson P, Jacobson IV. Down-regulation of KAI1/CD82 protein expression in oral cancer correlates with reduced disease free survival and overall patient survival. Cancer Lett 2004;213(1):91-98.
16. Nagira M, Imai T, Ishikawa I, Uwabe KI, Yoshie O. Mouse homologue of C33 antigen (CD82), a member of the transmembrane 4 superfamily: Complementary DNA, genomic structure, and expression. Cell Immunol 1994;157(1):144-157.
17. Suzuki H, Dong JT, Gao AC, Barrett JC, Isaacs JT. Identification of the rat homologue of KAI1 and its expression in Dunning rat prostate cancers. Prostate 1998;37(4):253-260.
18. Fukudome K, Furuse M, Imai T, Nishimura M, Takagi S, Hinuma Y, Yoshie O. Identification of membrane antigen C33 recognized by monoclonal antibodies inhibitory to human T-cell leukemia virus type 1 (HTLV-1)-induced syncytium formation: Altered glycosylation of C33 antigen in HTLV-1-positive T cells. J Virol 1992;66(3):1394-1401.
19. Sambrook J, Fristsch EF, Maniatis T. Molecular cloning: A laboratory manual. New York: Cold Spring Harbor Laboratory; 1989.
20. Ward JM, Konishi N, Ohshima M, Lamb PW, Jorcyk CL, Barrett JC. Expression of KAI1 in paraffin-embedded normal, hyperplastic and neoplastic prostate and prostate carcinoma cell lines. Pathol Int 1998;48(2):87-92.
21. Shappell SB, Thomas GV, Roberts RL, Herbert R, Ittmann MM, Rubin MA, Humphrey PA, Sund berg JP, Rozengurt N, Barrios R, Ward JM, Cardiff RD. Prostate pathology of genetically engineered mice: Definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res 2004;64(6):2270-2305.